Non-inferiority designs comparing placebo to a proven therapy for childhood pneumonia in low-resource settings.

CONCLUSION: In the setting where the benefit of a previously established beneficial treatment is questioned, a non-inferiority design that includes placebo as the tested treatment option can be the most appropriate design option. PMID: 31814441 [PubMed - as supplied by publisher]
Source: Clinical Trials - Category: Research Authors: Tags: Clin Trials Source Type: research

Related Links:

AbstractOmadacycline is a novel aminomethylcycline antibiotic developed as a once-daily, intravenous and oral treatment for acute bacterial skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia (CABP). Omadacycline, a derivative of minocycline, has a chemical structure similar to tigecycline with an alkylaminomethyl group replacing the glycylamido group at the C-9 position of the D-ring of the tetracycline core. Similar to other tetracyclines, omadacycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline possesses broad-spectrum antibacterial activit...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Abstract Delafloxacin is a novel fluoroquinolone with activity against Gram-positive, Gram-negative and atypical pathogens, including fluoroquinolone non-susceptible MRSA. The microbiological results of a phase 3 clinical trial in community acquired pneumonia comparing delafloxacin [300 mg IV with option to switch to 450 mg orally every 12h to moxifloxacin 400 mg IV with option to switch to 400 mg orally QD] were determined. Patients from 4 continents, predominately Europe but also South America, and Asia, were enrolled. The microbiological intent-to-treat (MITT) population included 520 patients and 60.5% of these...
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research
The World Health Organization earlier this year called antimicrobial resistance—pathogens’ ability to evade medical interventions—one of the 10 largest threats to global health. In the U.S. alone, according to a recent Centers for Disease Control and Prevention (CDC) report, 35,000 people die each year due to antibiotic-resistant infections. A new study published in the BMJ points to one major propagator of the problem: doctors are prescribing antibiotics when they shouldn’t. In fact, up to 43% of U.S. antibiotic prescriptions may be “inappropriate,” according to the research. Antibioti...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Research Source Type: news
Abstract Omadacycline is an effective therapy for community-acquired bacterial pneumonia (CABP). Given its potent activity against methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA), we sought to determine the pharmacodynamic activity and target PK/PD exposures associated with therapeutic effect in the neutropenic mouse pneumonia model against 10 MSSA/MRSA strains. The area under the concentration-time curve (AUC)/MIC associated with 1-log kill was noted at 24h ELF and plasma AUC/MIC exposures of ∼2 (ELF range
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research
Abstract Clinical and historical data underscore the ability of influenza viruses to ally with Staphylococcus aureus and predispose the host for secondary bacterial pneumonia, which is a leading cause of influenza-associated mortality. This is fundamental because no vaccine for S. aureus is available and the number of antibiotic-resistant strains is alarmingly rising. Hence, this leaves influenza vaccination the only strategy to prevent postinfluenza staphylococcal infections. In the present work, we assessed the off-target effects of a Tnms42 insect cell-expressed BEI-treated Gag-VLP preparation expressing the HA...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Publication date: December 2019Source: Infectious Disease Clinics of North America, Volume 33, Issue 4Author(s): Jeffery Ho, Margaret Ip
Source: Infectious Disease Clinics of North America - Category: Infectious Diseases Source Type: research
ACS Applied Materials&InterfacesDOI: 10.1021/acsami.9b15118
Source: ACS Applied Materials and Interfaces - Category: Materials Science Authors: Source Type: research
Abstract The bacterial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) is a potentially fatal disease, featured with extensive infection, inflammation, and airway dysfunction. With the increasing emerging of drug-resistant strains, new therapeutic strategies beyond canonical antibiotic treatment are pressingly needed. Daphnetin (DAPH) is a natural coumarin derivative with anti-inflammation, anti-microorganism and anti-oxidative properties. However, the protective effect of DAPH on S. aureus-caused pneumonia and the mechanism involved are never explored. Here we show that DAPH treatment confe...
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Tags: Int Immunopharmacol Source Type: research
In conclusion, we demonstrated that the selective boosting of lung innate immunity is a conceptually advantageous approach for improving the effectiveness of antibiotic treatment and fighting antibiotic-resistant bacteria. Introduction Pneumonia constitutes a major cause of death, morbidity and health resource use worldwide. The main causative agents identified in adult patients hospitalized for community-acquired pneumonia (CAP) are viruses (in 27–30% of cases, the most common being rhinovirus, influenza and coronavirus) and bacteria (14–23% of cases, with a marked predominance of Streptococcus pneumonia...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
ConclusionsThe potent activity of omadacycline against Gram-positive and Gram-negative bacteria indicates that omadacycline merits further study in serious infections in which multidrug resistance and mixed Gram-positive and Gram-negative infections may be a concern.
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
More News: Amoxicillin | Bacterial Pneumonia | Children | Clinical Trials | Malawi Health | Pneumonia | Research | Superbugs